Doctors stunned by a cheap drugs power against colon cancer

A Scandinavian clinical trial has revealed that low-dose aspirin can halve the risk of colon and rectal cancer recurrence in patients with specific genetic mutations. The research, involving over 3,500 patients, is the first randomized study to confirm aspirins powerful effect in this context. The findings suggest aspirin could become a widely available, inexpensive precision medicine, reshaping cancer treatment strategies globally.